Hengrui Medicine's JAK1 inhibitor secures another major indication

On June 30, 2025, according to information from the official website of the National Medical Products Administration (NMPA), Jiangsu Hengrui Medicine Co., Ltd.'s Class 1 new drug, alemcitinib (Aisuda®), was officially approved for the treatment of severe alopecia areata in adults, becoming the first domestically developed oral targeted therapy for alopecia areata in China (Application number: CXHS2400089).

This marks the fourth indication that Aisuda® has secured this year, following ankylosing spondylitis, rheumatoid arthritis, and atopic dermatitis.

Elsubrutinib® is China's first independently developed highly selective JAK1 inhibitor, featuring an optimized structure of "two bicyclic rings plus one monocyclic ring," enabling precise "lock-and-key" matching with JAK1.

The approval of this newly added indication brings a "Chinese innovative solution" to the clinical management of alopecia areata.